parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.04 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in bergmann glia	0.75
chemistry Open Targets	hard to drug	0.27
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 5905

receipt 5912: BBS2 in dopamine neurons, braak

power: full sample -0.16 (p 0.532, n 18), 95% CI -0.58 to +0.33. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.19 (p 0.455, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.14 (p 0.591, n 18). could be the mix.
skeptic: leave-one-out range -0.29 to -0.04, sign flips 0; without severely affected donors -0.16 (p 0.532, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for BBS2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 5911: BBS2 in astrocytes, braak

power: full sample -0.07 (p 0.781, n 18), 95% CI -0.52 to +0.41. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.07 (p 0.781, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.01 (p 0.983, n 18). could be the mix.
skeptic: leave-one-out range -0.21 to +0.01, sign flips 1; without severely affected donors -0.07 (p 0.781, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for BBS2 in astrocytes.

case closed: nothing better to follow up.

loading the receipts